Condition: Primary Hyperoxaluria Type 1 · End Stage Renal Disease · Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | San Francisco, California, United States | Active Not Recruiting |
| Clinical Trial Site | Boston, Massachusetts, United States | Active Not Recruiting |
| Clinical Trial Site | Rochester, Minnesota, United States | Recruiting |
| Clinical Trial Site | New York, New York, United States | Active Not Recruiting |
| Clinical Trial Site | Bron, France | Withdrawn |
| Clinical Trial Site | Paris, France | Withdrawn |
| Clinical Trial Site | Bonn, Germany | Recruiting |
| Clinical Trial Site | Heidelberg, Germany | Withdrawn |
| Clinical Trial Site | Roma, Italy | Withdrawn |
| Clinical Trial Site | Beirut, Lebanon | Recruiting |
| Clinical Trial Site | Casablanca, Morocco | Withdrawn |
| Clinical Trial Site | Oradea, Romania | Withdrawn |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04580420